Finch Therapeutics Group, Inc.
FNCH · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.00 | -0.00 | -0.16 |
| FCF Yield | 0.00% | -543.90% | -336.51% | -17.55% |
| EV / EBITDA | -2.60 | -0.33 | -0.05 | -6.00 |
| Quality | ||||
| ROIC | -38.62% | -59.37% | -61.32% | -27.03% |
| Gross Margin | 0.00% | -1,320.56% | -539.61% | -209.08% |
| Cash Conversion Ratio | 0.42 | 0.65 | 1.15 | 0.80 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -82.06% | -51.86% | 22.21% |
| Free Cash Flow Growth | 0.00% | 59.10% | 7.32% | -144.73% |
| Safety | ||||
| Net Debt / EBITDA | -1.28 | -0.15 | 0.23 | 2.21 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | -1.57 | -6.32 |
| Cash Conversion Cycle | -310.46 | -33.86 | -244.50 | -71.88 |